The avandia debacle: Methodology and practical importance of the findings

Southern Medical Journal

Volumn 100, Issue 11, 2007, Pages 1062-1063

  Meneghini, Luigi Fernando ^a,b   Florez, Hermes ^a   Tamariz, Leonardo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PLACEBO; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; NOTE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 35948963263     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181581a24     Document Type: Note

References (5)

1. Nissen SE, Wolski KW. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356 2457-2471.
2. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
3. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.
4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726-1735.
5. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.